DNA Today: A Genetics Podcast

#354 How Pharmacogenomics is Revolutionizing Drug Prescriptions

Aug 15, 2025
Kathleen O’Brien, a board-certified genetic counselor specializing in pharmacogenomics and hereditary oncology, and Kristy Bouvier, a product manager overseeing PGx offerings at Quest Diagnostics, explain how DNA shapes drug response. They walk through PGx test types and reports. They discuss real-world gene–drug examples, clinical adoption challenges, keeping tests current, and access and insurance issues.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
ADVICE

Verify Panel Content Before Ordering

  • Check which genes and alleles a PGx panel includes before ordering because content varies widely.
  • Kristy Bouvier notes Quest's polypharmacy panel includes 17 genes and 4 HLA alleles with high-evidence associations.
INSIGHT

PGx Cuts Adverse Reactions

  • PGx-guided prescribing reduces adverse drug reactions and can alter dosing or choice of medication.
  • Kathleen O’Brien cites the PREPARE study showing about a 30% reduction in adverse drug reactions.
INSIGHT

Genetics Predicts Severe Drug Toxicity

  • Specific gene variants (e.g., DPYD, HLA alleles) can predict severe toxicity to chemotherapy or immune-mediated reactions.
  • Kathleen O’Brien explains how knowing variants lets clinicians change dose, choose alternatives, or monitor more closely.
Get the Snipd Podcast app to discover more snips from this episode
Get the app